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CXCR3 is involved in numerous inflammatory disorders such as rheumatoid arthritis, multiple 
sclerosis, allograft rejection and inflammatory bowel disease.  There is a strong and growing 
demand for novel and effective therapeutics that can mediate CXCR3 activity.  In this study, a 
set of botanical compounds and a peptide mimetic of the second extracellular loop (ECL-2) of 
CXCR3 were examined for the ability to inhibit interactions between CXCR3 and its ligands in a 
murine model.  EGCG, a green tea polyphenol, and gallotannin, derived from many plant 
sources, strongly inhibited the chemotaxis of stably transfected murine CXCR3-expressing L1.2 
cells in response to murine CXCL9, CXCL10, and CXCL11.  EGCG was also shown to bind directly 
to murine CXCR3 ligands with high affinities.  Baicalin, a flavonoid found in the medicinal plant 
Scutellaria baicalensis, and ginkgolide A, from the Ginkgo biloba tree, did not significantly 
reduce cell migration towards murine CXCR3 ligands, nor did the peptide mimetic of the ECL-2 
of murine CXCR3.  Other green tea polyphenols similar in structure to EGCG were also analyzed 
and were less able to inhibit murine CXCR3 ligand-mediated chemotaxis than EGCG, with the 
following efficacies: ECG > EGC > EC.  It was observed that the most effective test compounds 
contained more hydroxyl groups and hence were more negatively charged, similar to 
glycosaminoglycans, which are extracellular matrix components that bind many chemokines.  It 
is possible that EGCG and gallotannin are able to bind the GAG-binding domains of murine 
CXCR3 ligands, which allows them to prevent receptor binding and inhibit their function.  This 
possibility represents the public health relevance of this research, as EGCG and gallotannin may 
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be attractive candidates as lead compounds for new therapeutics for CXCR3-mediated and 
other inflammatory diseases. 
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CHAPTER 1:  INTRODUCTION 
 
1A. Overview 
The body’s immune response to a microbial pathogen can play a major role in 
determining disease outcome.  The type of response mounted by the immune system can 
determine how efficiently the body clears the pathogen, if at all.  Chemokines and chemokine 
receptors are integral parts of the immune system, as they mediate the recruitment of specific 
immune cells during immune induction events and to sites of infection and inflammation.  For 
example, one of the functions of chemokine receptor CXCR3 and its ligands is to regulate the 
trafficking of activated T cells to sites of infection and inflammation.  The ability to manipulate 
chemokine-chemokine receptor interactions may serve as a valuable tool for developing 
therapeutics to aid the host in combating certain pathogens or to ameliorate chronic 
inflammation.  While chemokines and their receptors play significant roles in fighting 
infections, they also contribute to numerous pathological inflammatory conditions, such as 
arthritis and multiple sclerosis.  Thus, compounds that can modulate chemokine-chemokine 
receptor interactions may also be beneficial in alleviating the consequences of excessive 
inflammation. 
I have investigated in the studies described in this thesis two types of agents that may 
modulate chemokine-chemokine receptor interaction: botanically-derived compounds and 
chemokine receptor peptide mimetics.  Specifically, I examined the effects of several plant-
derived compounds like epigallocatechin-3-gallate (EGCG), the major polyphenol in green tea, 
which has been discovered to mediate CXCR3-ligand interactions (unpublished data).  I also 
investigated the inhibitory effects of a peptide mimetic of the second extracellular loop 
segment of the CXCR3 receptor.  We have named this peptide X3P3, and it may be able to alter 
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CXCR3-ligand interaction by binding the ligand (unpublished data).  Our preliminary data 
suggest that both X3P3 and EGCG can bind chemokines, which may block or alter the 
interaction with the chemokine receptor. 
These previous in vitro studies examined the effects of X3P3 and EGCG on human 
chemokines and their chemokine receptors.  However, we anticipate the progression from in 
vitro to in vivo experiments performed in a small animal model, such as a murine model.  I have 
performed studies using a murine chemokine receptor in order to facilitate this transition, and 
I have developed a model with which I tested the hypothesis that several botanically-derived 
compounds and X3P3 can inhibit murine CXCR3 (mCXCR3) ligand function.   I used this model 
to accomplish my two main objectives: to identify and investigate compounds that will 
modulate mCXCR3-ligand interactions, and to begin shifting these experiments to an in vivo 
setting.   
 
1B. Background 
 
1B.1. Chemokines 
Chemokines are small, structurally-related, chemotactic proteins that regulate 
leukocyte migration by interacting with seven transmembrane G protein-coupled receptors.  
They are intimately involved in physiologic processes, including inflammation1, 
hematopoiesis2, wound healing3, angiogenesis4, organogenesis5, embryonic development6 and 
tumor growth and metastasis7.  Most chemokines and chemokine receptors are promiscuous in 
binding, as many receptors can bind multiple ligands and individual chemokines can often bind 
multiple receptors8. 
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Chemokines can be classified into four groups based on the positioning of cysteine 
motifs near the N-terminus: C, CC, CXC, CX3C, where X denotes any amino acid9.  Alternatively, 
they can be described by function: homeostatic or inflammatory.  Homeostatic chemokines are 
constitutively expressed in discrete tissues and are responsible for the homeostatic trafficking 
of leukocytes and hematopoietic progenitor cells10.  For example, CXCL12 – also known as 
stromal cell-derived factor-1 (SDF-1) – contributes to the migration, homing and survival of 
hematopoietic stem cells and hematopoietic progenitor cells11.  In contrast, inflammatory 
chemokines are expressed at sites of inflammation when cells are stimulated by pathogens or 
pro-inflammatory cytokines like IL-1β or TNF-α12.  This set of chemokines, in turn, recruits T 
cells, natural killer (NK) cells, monocytes, and granulocytes to inflamed tissues.  Examples of 
inflammatory chemokines are CXCL9, CXCL10, and CXCL11, which all share a common 
receptor, CXCR3. 
 
1B.2. CXCR3 
CXCR3 is a chemokine receptor expressed on a wide range of cells, mainly on activated 
T lymphocytes and, to a lesser extent, on resting T lymphocytes, NK cells, B cells13, and 
endothelial cells14.  Its main ligands are IFN-γ inducible chemokines CXCL9, CXCL10, and 
CXCL11, formerly known as monokine induced by interferon-γ (Mig), interferon-γ inducible 
10-kDa protein (IP-10), and interferon-inducible T cell α chemoattractant (I-TAC)15. 
A chief function of CXCR3 and its ligands is to modulate the migration of activated T 
cells to sites of inflammation as part of Th1-type immune responses.  These chemokines have 
also been shown to induce chemotaxis of NK cells16, dendritic cells17, and macrophages18.  The 
three main CXCR3 ligands, CXCL9, CXCL10, and CXCL11, share 40% amino acid homology with 
each other, which is higher than any other chemokine-chemokine homology19.  Of these three 
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ligands, CXCL11 binds CXCR3 with the strongest affinity20.  CXCL13 and CXCL4 have also been 
suggested to bind CXCR3 and are able to activate it at high concentrations21, also causing T-cell 
migration22.  In addition, CXCR3 has also been shown to bind to CCL21, a ligand for CCR7, in 
mice23. 
CXCR3 is composed of 368 amino acids and is a seven-transmembrane G-protein 
coupled receptor24.  It is mainly found in two alternatively spliced forms – CXCR3-A and CXCR3-
B.  A third splice variant, CXCR3-alt, was discovered in 200425.  CXCR3-A was discovered first in 
199626.  CXCR3-B, however, was discovered in 2003 and can bind CXCL4 at a higher affinity, in 
addition to the main CXCR3 ligands.   Studies have revealed that the differences in protein 
structure translate to different functions in vitro. 
CXCR3-B was discovered while investigating the angiostatic effects of CXCL9, CXCL10, 
and CXCL11, as well as CXCL427.   When interacting with CXCR3 on human mesangial cells 
(HMC), the three main CXCR3 ligands promoted cell proliferation28.  However, when binding 
the receptor on human microvascular endothelial cells (HMEC), they inhibited growth and 
induced cell death.  These seemingly contradictory effects were explained by the discovery of 
two different forms of CXCR3.  It was found that HMCs expressed CXCR3-A, while HMECs 
expressed CXCR3-B – and these two forms of the receptor had two opposite functions.  
Although both forms of CXCR3 can bind CXCL9, CXCL10 and CXCL11, the CXCR3-A form has a 
higher affinity for them and will outcompete CXCR3-B29.  Thus, if a cell type expresses CXCR3-B 
and CXCR3-A simultaneously, its CXCR3-A receptors will predominantly interact with 
chemokines instead.  These two forms of the receptor operate by different signaling pathways, 
and thus lead to different outcomes when activated30. 
CXCR3-alt encodes a truncated version of the receptor 260 amino acids in length31 and 
is predicted to have four or five transmembrane domains.  Chemotaxis studies show that this 
 5 
change in structure abolishes the receptor’s ability to interact with CXCL9 and CXCL10, but the 
receptor retains functional activity when interacting with CXCL11.  Generally it is expressed at 
lower levels than full-length CXCR3.   
CXCR3 and its ligands are suspected to be involved in inflammatory diseases such as 
atherosclerosis32, acute allograft rejection33, multiple sclerosis34, inflammatory bowel disease35, 
psoriasis36, sarcoidosis37, type I diabetes mellitus38, and rheumatoid arthritis39.  For instance, 
during development of diabetes mellitus, insulin-secreting beta cells are targeted by self-
reactive CXCR3-positive T cells.  Beta cells produce CXCL9 and CXCL10, which attract the T cells 
that ultimately destroy them40.   A possible therapy for these numerous diseases may entail 
modulating the CXCR3-ligand interaction, and this possibility is of particular interest in 
chemokine research. 
CXCR3 and its ligands have been shown also to play a role in cancer.  CXCL9, CXCL1041, 
and CXCL442 regulate tumor growth by causing damage to tumor-associated vasculature, 
leading to tumor necrosis43.  Numerous studies have investigated these chemokines as possible 
cancer therapeutics.  In a recent study using a murine model of metastatic renal cell carcinoma 
(RCC), treatment with IL-2 and CXCL9 greatly reduced tumor size, impaired angiogenesis, and 
stimulated tumor necrosis44.   However, two studies – also using murine models – implicate 
that CXCR3 may also be involved in colon cancer45 metastasis to lymph nodes and breast 
cancer46 metastasis to the lung.  In the breast cancer study, treatment of mice with AMG487, a 
CXCR3 antagonist, inhibited metastasis to the lung.  Amgen’s AMG487 is the first small 
molecule CXCR3 inhibitor to enter clinical trials47, and this study was the first to report that a 
small molecular weight CXCR3 inhibitor was able to decrease tumor metastasis. 
Another small molecule CXCR3 antagonist is NBI-74330, and both AMG487 and 
NBI74330 were included in a study by Verzijl et al.48.  It was found that both compounds are 
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noncompetitive antagonists of CXCR3 and have a lower affinity for rodent CXCR3 compared to 
the human form of the receptor.  The objective of this study was to enhance the understanding 
of these antagonists in animal models because they may be able to prevent or treat CXCR3-
related diseases.  Another study using NBI-74330 was undertaken by van Wanrooij et al.49, and 
it reports that NBI-74330 treatment can reduce diet-induced plaque formation in LDL 
receptor-deficient mice.  The complex role of CXCR3 and its ligands in biological processes and 
diseases makes them interesting targets of further research. 
 
1B.3. Botanicals 
Botanically-derived compounds are attractive targets for chemotherapeutic 
development, as they are believed to exhibit low levels of toxicity and few side effects.  Such 
anti-inflammatory compounds may be able to inhibit CXCR3-ligand interactions.  The 
compounds I have investigated here included epigallocatechin-3-gallate (EGCG), baicalin, 
gallotannin, and ginkgolide A.  The structure of each compound, as well as structurally related 
compounds, is illustrated in Figure 1. 
EGCG, the most abundant polyphenol in green tea, is known to exert a host of health 
benefits both on tea-drinkers and animal subjects.  Among these benefits are the suppression of 
inflammation50, prevention of cancer, inhibition of tumor growth, protection of DNA from 
damage, induction of apoptosis in tumor cells, and antioxidant effects51.  One mechanism by 
which these botanicals inhibit inflammation might be by binding directly to chemokines, and 
preventing them from interacting with their receptor(s).  Our preliminary studies support this 
theory, and I have examined these effects specifically on murine CXCR3 (mCXCR3) and its 
ligands. 
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Baicalin, a flavonoid derived from the Chinese herb Scutellareia baicalensis, is a major 
constituent in herbal medicines used to treat chronic hepatitis in China and Japan52.  It has been 
shown in one study to inhibit inflammation by binding to a subset of chemokines53, including 
CXCL8, CXCL12, CCL4 (MIP-1β), and CCL8 (MCP-2).  Chemotaxis assays revealed that baicalin 
suppresses  each chemokine’s ability to stimulate cell migration.  Its activity, however, is 
limited to a subset of chemokines, as it had no effect on CX₃CL1, nor on the cytokines TNF-α or 
IFN-γ.  Li et al.54 suggest that baicalin interacts selectively with chemokines of the CXC, CC, and 
C classes and not CX3C chemokines or other cytokines.  In this case, since CXCR3 ligands are 
CXC chemokines, baicalin may also bind them. 
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Gallotannin, or tannic acid, is a polyphenol and a hydrolyzable tannin, found in many 
plants55.  Multiple studies show that it, like EGCG and baicalin, possesses anti-inflammatory 
properties56.  It is also suggested to have anti-viral and anti-cancer effects.  Non-toxic amounts 
of gallotannin were found to selectively inhibit chemotactic properties of CXCL12 and decrease 
binding of the chemokine to THP-1 cells57.  In addition, Erdèlyi et al. demonstrated that the 
compound reduces expression of several inflammatory chemokines and receptors in human 
lung adenocarcinoma (A459) cells58.  They postulated that gallotannin targets the NF-kB 
pathway to inhibit expression of CXCR4 and CCL20. 
Ginkgolides are terpene trilactones found in the leaves and root bark of the Gingko 
biloba tree59.  The leaves of the Gingko tree have traditionally been used in Chinese herbal 
medicine, and Gingko leaf extract has recently been used to treat cerebral vascular 
insufficiency, or deficient blood flow to the brain60.  Ginkgolides are known to be effective 
inhibitors of platelet activating factor (PAF)61, a molecule that induces platelet aggregation.  
PAF can also induce inflammation, allergic reaction, and asthma62.  Ginkgolide A, B, and C are 
structurally similar, and in the studies described here I focused on ginkgolide A. 
 
1B.4. Peptide Mimetics 
Peptide mimetics may also be strong candidates to modulate CXCR3-ligand interactions.  
They structurally resemble parts of proteins and can be designed to have extra properties that 
render them better drugs, such as protease resistance, targeted cellular transport, decreased 
toxicity, and fewer side effects63.  Our X3P3 peptide, for instance, is likely to be structurally 
similar to the second extracellular loop (ECL-2) of CXCR3 (Figure 2).  We have preliminary data 
that show that X3P3 designed based on the human CXCR3 sequence binds directly to CXCL9, 
CXCL10, and CXCL11 and inhibits CXCR3-mediated chemotaxis.  Since it has been shown that 
 9 
human and murine CXCR3 are 86% identical64, it seems reasonable to hypothesize that a 
murine X3P3 peptide might also bind murine CXCR3 ligands. 
Peptide mimetics have been studied only minimally in the context of HIV.  Synthetic 
peptides mimicking CCR5, a coreceptor for HIV-1, have been shown to inhibit viral fusion and 
entry65.  The peptides studied to date are those modeled after the amino-terminal domain66 and 
the extracellular loops of CCR5.  Sulfotyrosine-containing peptides resembling the N-terminus 
of CCR5 inhibited entry of a CCR5-tropic strain, while replicas of the second and third 
extracellular loops of the receptor prevented entry of R5 and R5X4 strains.  These peptides 
show potential for becoming innovative and effective HIV therapeutics.  
 Peptides representing N-terminal regions of CXCR3 were used by Colvin et al. to 
determine whether tyrosine sulfation of CXCR3 is necessary for ligand binding67.  In this study, 
sulfated N-terminal peptides were found to inhibit CXCL10- and CXCL11-induced chemotaxis, 
confirming that it is possible for a peptide mimetic of an extracellular region of CXCR3 to 
inhibit CXCR3 function.    
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CHAPTER 2: STATEMENT OF THE PROJECT 
 
2A. Overview.  The main objective of this project was to develop an in vitro murine model for 
identifying and studying compounds that that might inhibit interactions between murine 
CXCR3 and its ligands.  Included in these studies were natural plant-derived compounds as well 
as a peptide mimetic of the second extracellular loop of CXCR3.  If murine cells are sensitive to 
chemotaxis inhibition in a manner similar to human cells, the murine model may be a suitable 
choice for in vivo studies of CXCR3 inhibition.  Lead compounds may then be investigated 
further as possible therapeutics for CXCR3-mediated inflammatory disorders.   
 
2B. Specific Aims. 
 
1. To examine the inhibitory effects of botanically-derived compounds on interactions 
between mCXCR3 and its ligands.  Our preliminary data indicated that EGCG, a green tea 
polyphenol, inhibits chemokine function in a dose-dependent manner by binding 
directly to human CXCR3 ligands (unpublished data).  Because EGCG is able to inhibit 
CXCR3-mediated chemotaxis, my hypothesis was that it and other botanical compounds 
might also inhibit the function of murine CXCR3 ligands.   
 
2. To investigate the effects of the X3P3 peptide on mCXCR3 ligand function.  Our previous 
studies indicated that human X3P3 binds directly to chemokines and thereby inhibits 
their functions.  However its inhibitory effects on interactions between murine CXCR3 
and its ligands were previously unknown.  Because of the similarities in structure and 
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function between murine and human CXCR3, I hypothesized that a murine X3P3 peptide 
will be able to modulate the mCXCR3-ligand interaction. 
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CHAPTER 3: MATERIALS AND METHODS 
 
3A. Overview.  To set up a system with which to examine the inhibitory effects of the 
botanicals or a CXCR3 peptidergic mimetic, I first generated cell lines that respond to murine 
CXCR3 ligands.  The chosen parental cell line was the murine pre-B cell line L1.2, which did not 
respond chemotactically to CXCR3 ligands.  An existing murine CXCR3 cDNA was transfected 
into L1.2 cells, and the resulting cell lines were screened via chemotaxis assay for high 
migratory ability towards mCXCL11.  The highest migraters were then used in chemotaxis 
inhibition assays to determine if the peptide mimetic and botanical compounds were able to 
inhibit chemotaxis. 
 
3B. Cloning. To clone the mCXCR3 cDNA into a mammalian expression, the mCXCR3 cDNA was 
PCR-amplified mCXCR3 using pGEMT_mCXCR3.1 previously generated by Kristi Gaus in our 
laboratory as a template.  I constructed primers (Integrated DNA Technologies) containing a 
GCC clamp at the 5’ end and restriction sites corresponding to sites within pcDNA3.1(+), the 
mammalian expression vector used for these studies.  The forward primer sequence was 5’-
GCCGAATTCATGTACCTTGAGGTTAGTGA-3’, containing a restriction enzyme site recognized by 
EcoRI.  The reverse primer sequence read 5’-GCCCTCGAGTTACAAGCCCAGTAGGAG-3’, with an 
XhoI site.  These primers were successfully used with Gotaq DNA polymerase (Promega) to 
amplify the mCXCR3 sequence and add restriction enzyme sites.  The conditions for the PCR 
cycles were 3.5 minutes at 94° for denaturation, 30 seconds at 56° for annealing, 2 minutes at 
72° for extension, and 10 minutes at 72° for final extension.  Samples were run for 35 cycles.  
DNA in the sample was visualized by gel electrophoresis performed on 0.8% agarose gel, using 
GelRed (Biotium). 
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To obtain pcDNA3.1(+) vector and mCXCR3 insert with compatible cohesive ends, 
pcDNA3.1_huCCR4 (University of Missouri cDNA Resource Center) and the PCR-amplified 
mCXCR3 product were digested with EcoRI and XhoI (NEB) for 3 hours at 37°.  The digestion 
products were separated by gel electrophoresis (Figure 1B), and appropriate DNA fragments 
were extracted (Qiagen Qiaex II Gel Extraction Kit).  Then, the pcDNA3.1(+) and mCXCR3 
fragments were ligated together and used to transform DH5α competent cells (Invitrogen).  
Digested mCXCR3 PCR product was also ligated with pGEM_T (Promega).  This was a 
precautionary step performed in case the ligation between mCXCR3 and pcDNA3.1 was 
unsuccessful.  Transformation products were plated on LB/ampicillin plates and incubated at 
37° overnight.  Subsequent colonies were picked and screened for the correct insert. 
 
3C. Verification of the correct insert sequence in pcDNA3.1_mCXCR3.  To ensure that the 
ligations were successful, I subjected the clones to colony PCR, and their DNA to restriction 
digest and DNA sequencing.  To perform colony PCR, I used the primers mentioned in section 
D1.  Colonies were picked from each of these plates: pcDNA3.1 ligated with mCXCR3, pGEM-T 
ligated with mCXCR3, and pGEM-T ligated with control insert.  They were put into PCR mixes, 
and samples were run through the same steps described above. Colony PCR was performed on 
18 clones, including one clone transformed with pGEM-T ligated with the manufacturer’s 
control plasmid.  PCR products were then run on a 0.8% agarose gel and visualized.  Each clone 
appeared to yield PCR product, including the clone transformed with a plasmid that did not 
contain mCXCR3.   
To determine whether these clones’ DNA contained mCXCR3, I chose four clones based 
on the colony PCR results and extracted their DNA by mini prep (Promega Pure Yield DNA 
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Extraction Kit).  I chose two clones resulting from the pcDNA3.1(+) and mCXCR3 ligation, one 
from the pGEM-T and mCXCR3 ligation, and one containing pGEM-T and the control insert.  The 
DNA from the four clones was then digested with EcoR1 and XhoI, and the resulting DNA 
fragments were separated and visualized by gel electrophoresis.   
Next, the DNA from clones #1 and #2 was further analyzed by PCR using vector-specific 
primers.  The two sets of primers were T7 and R800, and BGH and F300.   T7 and BGH are 
specific to the vector, pcDNA3.1(+), whereas R800 and F300 are specific to the insert sequence, 
mCXCR3.  PCR conditions were the same as described in section 3B. 
 
3D. Transient transfection and mCXCR3 expression confirmation.  The pcDNA3.1_mCXCR3 
plasmids were sequence-confirmed and transfected via electroporation (Biorad Gene Pulser II) 
into murine L1.2 cells.  Cells were deposited into an electroporation tube (Bio-Rad) along with 
yeast tRNA (Ambion) and 10 μg of DNA, then pulsed for approximately  15 milliseconds 
seconds at 330 volts and 0.975 uF.  To test for mCXCR3 expression, transiently transfected cells 
were stained with a PE-conjugated anti-mCXCR3 antibody (R&D, catalog #FAB1685P, clone 
220803) and isotype control (R&D, catalog #IC006P) and analyzed by flow cytometry on a 
FACSCanto flow cytometer (Becton Dickinson).  Flow data were analyzed using Flowjo 
software (Treestar).  To test for functionality of the receptor, a chemotaxis assay was 
performed.  After a 24-hour incubation, cells were washed and resuspended in RPMI-1640 and 
0.1% bovine serum albumin (BSA) at 200,000 cells/ml.  Different concentrations of murine 
CXCL9 (Peprotech), solubilized in water, were placed on the bottom of a chemotaxis plate 
(Neuroprobe, #101-5), and a membrane with 5-μm pores was placed on top of the plate.  Cells 
were placed on top of the membrane, and incubated for 3 hours at 37° at 5% CO₂ in a 
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humidified box.  After the incubation, cells that migrated through the membrane were counted 
using a hemacytometer.   
 
3E. Establishment of stable murine cell line expressing mCXCR3.  To develop a murine cell 
line stably expressing mCXCR3, L1.2 cells were transfected with pcDNA3.1(+) expression 
plasmids via electroporation  with the same conditions described above.  To select for cells that 
incorporated plasmid into their genomes, geneticin (Gibco Life Technologies) was used at 1 
mg/mL.  Cells were diluted to 20,000 cells per 150 μL, then aliquots of 150 μL of culture were 
loaded into a flat-bottom 96-well plate (Corning) and monitored for growth.  Then, wells 
containing typically a single focus of cells were chosen for further cultivation and grown in 
media with geneticin in 24-well plates.  These cells were tested for expression of mCXCR3 by 
flow cytometry and chemotaxis, and the clones that migrated at the highest levels towards 1nM 
mCXCL11 were chosen.  To generate secondary clones, cultures of highly migratory clones 
were diluted, and aliquots were placed into a 96-well plate with a ratio of one cell to every 
three wells.  This resulted in foci of cells growing from a single clone, and these single cell 
clones were screened for migratory responses to 1nM mCXCL11.  The clones showing the 
highest migration were chosen as the stable cell lines used in later stages of the project. 
I have also utilized an alternative way to screen for high migraters.  After primary 
clones were cultured in 24-well plates, they were tested for migration in a chemotaxis 
experiment.  Cells that have successfully migrated to the bottom of the membrane were  
removed from the chemotaxis plate and cultured.  These cells were then screened for high 
migration, and cultures with high migraters were diluted and plated into 96-well plates as 
above.   After foci of cells grew, single cell clones were cultured, and resulting cultures were 
tested for migration towards mCXCL11 at 1 nM.  The clones that showed the highest levels of  
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migration were chosen as the stable cell lines used later in the study.  Secondary clones that 
resulted from chemotactically-selected primary clones were designated an “s” in their name, 
i.e. 1E.s8 or 3E.s1. 
 
3F. Preparation of test compounds.  Test compounds were resuspended in either nuclease-
free water (Ambion) or a mixture of dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and nuclease-
free water.  Murine X3P3 (University of Pittsburgh Peptide Facility) and EGCG  (Sigma-Aldrich, 
catalog #E4143) were water-soluble and were prepared by S. Qin and T. Reinhart, respectively.  
Gallotannin (Sigma-Aldrich, catalog #403040) was water soluble and therefore was also 
dissolved in water.  Baicalin (Sigma-Aldrich, catalog # 572667) and ginkgolide A (Sigma-
Aldrich, catalog # 51863) were slightly hydrophobic and thus were dissolved in a combination 
COMPOUND CONCENTRATIONS 
USED IN PAST 
STUDIES (μM) 
CONCENTRATIONS 
REACHED IN VIVO  
CONCENTRATIONS 
USED IN PRESENT 
STUDY (μM) 
EGCG 1, 10, 100 Humans: 
2.18  μM  (6-7 cups 
tea)68 
1, 10, 100 
Gallotannin 11.8, 23.5, 35.369 
30, 10070 
Unknown 1, 10, 50, 100 
Baicalin 2, 22.4, 224;71 
179.2, 71772 
Rats: 2.0 μM*73 1, 50, 100, 200 
Ginkgolide A 1, 3, 10, 3074; 
91.875 
Humans: 181.8  
μg/mL of GkA, GkB, 
and bilobalide**76 
1, 10, 40, 80 
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of DMSO and water.  Baicalin was resuspended at 11.72 mM in 75% DMSO, and ginkgolide A 
was dissolved in 75% DMSO at 24.5 mM. 
 
3G. Cytotoxicity assay.  To determine if the compounds studied exhibited cytotoxic effects at 
their working concentrations, cytotoxicity assays were performed.  First, a range of test 
concentrations were established based on concentrations found via literature review(Table 1).  
These concentrations were used during chemotaxis inhibition studies, and the highest of these 
test concentrations was used in cytotoxicity studies.  These studies were performed using the 
L1.2_mCXCR3.1E.s8 cell line, which was also used for the bulk of the chemotaxis inhibition 
studies.  Cell cultures were split once a day for three days at approximately 1:1 
culture:medium, and on the fourth day, one population of cells was treated with 5 mM sodium 
butyrate, while another population was not.  The two populations of cells were used to 
determine if sodium butyrate treatment affects cell viability during a chemotaxis experiment.  
After an overnight incubation, the two populations of cells were used for two separate but 
identical cytotoxicity assays.  Cells were placed into 96-well plates with the highest 
concentration of test compound to be used during chemotaxis studies, and then incubated for 
three hours at 37°C and 5% CO2 to simulate incubation conditions during a chemotaxis assay.  
After the incubation, live cells and dead cells were counted using a hemacytometer and trypan 
blue (BioWhittaker), a reagent that is excluded from live cells. 
 
3I. Chemotaxis and chemotaxis inhibition.  Chemotaxis assays were performed as 
described77 to measure the effects of the botanical compounds and the X3P3 peptide  on 
mCXCR3-ligand interactions.  Stable cell clones of L1.2 cells expressing mCXCR3 were treated 
with 5 mM sodium butyrate to induce mCXCR3 expression, and then incubated overnight.  
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Then, cells were washed and resuspended as described above.  Aliquots of 20 μl  of cells were 
deposited onto chemotaxis plates on top of the chemotaxis membrane.  Optimal concentrations 
of chemokine, as well as medium-only controls, were placed on the bottom of the membrane 
with different concentrations of the inhibitory compound.  The chemotaxis plate was left to 
incubate in a humid box for 3 hr at 37°C at 5% CO₂.  The cells that migrated through the 
membrane were counted using a hemacytometer.  Experiments were performed three times, 
with all samples in triplicate each time, unless otherwise noted.  Data were visualized using 
Prism (Graphpad) and statistical analyses were performed using Minitab software.  Paired t-
tests were used to compare migration levels to chemokine only versus chemokine plus 
compound.  If the compound was dissolved in a percentage of DMSO, the paired t-test 
compared migration levels towards chemokine plus DMSO and chemokine plus compound.  A 
statistical significance of p < 0.05 was used. 
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CHAPTER 4: RESULTS 
 
4A. Overview. The objective of these studies was to identify agents that could modulate 
interactions between mCXCR3 and its ligands and mCXCR3-mediated chemotaxis.  To 
accomplish this, I have designed a system in which the effects of such agents on mCXCR3 can be 
observed.  I first constructed a mammalian expression plasmid containing the mCXCR3 cDNA, 
and used this plasmid to generate cell lines expressing mCXCR3.  These cell lines were screened 
for high migratory capacity and a highly migratory cell clone expressing wild type mCXCR3 was 
used for the majority of the chemotaxis inhibition studies.  Use of these cells to study the 
chemotactic inhibitory properties of different compounds revealed that the botanicals EGCG 
and gallotannin were effective at inhibiting chemotaxis at concentrations that were not 
cytotoxic.  Baicalin and ginkgolide A were less effective at inhibiting chemotaxis.  Murine X3P3, 
which is a peptidergic mimetic of ECL2 of mCXCR3, was ineffective at inhibiting chemotaxis at 
the concentrations used.  Results for all test compounds were consistent for three cell clones: 
L1.2_mCXCR3.1E.s8 (wild type mCXCR3), L1.2_mCXCR3.2B.s5 (wild type mCXCR3), and 
L1.2_mCXCR3.3E.s4 (mutant mCXCR3).   
 
4B. Cloning.  The mCXCR3 DNA was amplified by PCR, and the resulting PCR product  was 
visualized by gel electrophoresis (Figure 3A).  Analysis of the gel confirmed that the primers 
were successful in amplifying the mCXCR3 sequence and revealed that the PCR product was of 
the correct size – approximately 1.6kb.  The murine CXCR3 ORF contains 1,608 base pairs.  The 
PCR product was gel extracted and digested, as was the vector pcDNA3.1(+) (Figure 3B).  The 
digestion products were ligated, and the resulting plasmid was used to transform the DH5α 
strain of E. coli.  Colony PCR was performed, and all clones appeared to contain the insert 
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(Figure 3C).  Four clones were expanded for small-scale DNA isolation.  Clones #1 and #2 
resulted from the pcDNA3.1 and mCXCR3 ligation, clone #3 resulted from the pGEM-T and 
mCXCR3 ligation and was included as a ligation control, and clone #17 contained pGEM-T and 
the control insert.  The plasmids were restriction digested and run on a gel (Figure 3D).  The gel 
revealed that clones #1 and #2, expected to be pcDNA3.1_mCXCR3, both contained an insert 
that was of the appropriate size expected for the mCXCR3 cDNA insert.  Clones #3 and #4 did 
not release a correctly sized insert, verifying that these plasmids did not contain mCXCR3. 
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 To further verify the identities of clones #1 and #2, I screened them via PCR using 
vector-specific primers.  I used two sets of primers: T7 and R800, and BGH and F300.  T7 and 
BGH are specific to the vector, pcDNA3.1(+), whereas R800 and F300 are specific to the insert 
sequence, mCXCR3.  Thus, PCR amplification of the template would only occur if the plasmid 
contained both vector and insert sequence.  For both samples, PCR product of the correct size 
was detected (Figure 3E).  The small band in the No DNA control is likely a result of spillover. 
To confirm that clones #1 and #2 contained the correct insert, DNA sequences were 
obtained through with the assistance of the the Genomics and Proteomics core laboratory.  The 
primers used were F300 and F700, which are mCXCR3-specific and were designed previously 
by Kristi Gaus, as well as the vector-specific primer T7.  The DNA sequences from the two 
clones were confirmed to contain mCXCR3 ligated to pcDNA3.1(+).  Restriction enzyme 
recognition sites corresponding to those within the pcDNA3.1 multiple cloning site (MCS) were 
identified, as was the ORF of mCXCR3.  The sequences derived here were compared to the 
mCXCR3 ORF sequence present in the GenBank database (GI: 118129823).  
The full amino acid sequence of pcDNA3.1_mCXCR3.1, aligned with the amino acid 
sequence of the mCXCR3 present in GenBank is shown in Figure 4. At the amino acid sequence 
level, the clones generated here are identical to the previously determined mCXCR3 sequence.    
Dots (•) denote identity with the amino acid in the reference sequence. 
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4C. Generation of mutant mCXCR3.  The first set of primers designed for PCR amplification of 
mCXCR3 cDNA contained two nucleotide substitutions that led to the creation of a mutant form 
of mCXCR3, designated mCXCR3_mut (Figure 5).  The two base pair substitutions, both guanine 
to cystidine, were made at amino acid positions 4 and 5 of the mCXCR3 ORF.  When translated, 
these substitutions will result in two amino acid changes, E4D to V5L.  Both human and murine 
CXCR3 contain glutamic acid and valine at positions 4 and 5, respectively, and they are part of 
the first 16 amino acid sequence at the N-terminus.  This sequence is thought to be required for 
binding to CXCL10 and CXCL11, but not to CXCL978.  Thus, the mutant mCXCR3 may not bind 
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mCXCL9 or may have reduced affinity for it.  If so, this mutant mCXCR3 could be used to 
examine ligand-specific modulation of mCXCR3.  
 
4D. Transient transfection and verification of mCXCR3 expression.  To confirm that the 
engineered pcDNA3.1 plasmids expressed mCXCR3 and that a commercially available antibody 
would detect it on cell surfaces, L1.2 cells were transiently transfected.  L1.2 cells are murine 
pre-B lymphoma cells that can be stimulated to migrate at high levels and can be transfected 
with high efficiencies.  The plasmids that were examined included pcDNA3.1_mCXCR3.1, 
pcDNA3.1_mCXCR3.2, pcDNA3.1_mCXCR3.m1, and pcDNA3.1_mCXCR3.m2.  The plasmids 
pcDNA3.1_mCXCR3.1 and pcDNA3.1_mCXCR3.2 encoded wild type mCXCR3 and were derived 
from separate bacterial colonies following transformation of E. coli with a sequence-confirmed 
pcDNA3.1 clone containing the mCXCR3 cDNA .  Similarly, the other two plasmids encoded the 
mutant form of mCXCR3 and were also products of two colonies from the same bacterial 
transformation.  As controls, L1.2 cells were transfected in parallel with just the vector 
pcDNA3.1(+), with pEGFP-N1, or without DNA.  All transfected cells were treated with sodium 
butyrate four to five hours after transfection.  After culturing cells overnight, cells were stained 
with an anti-mCXCR3 antibody or isotype control and examined by flow cytometry.  The 
resulting data were analyzed using Flowjo software.  Transfections were successful, as 
evidenced by successful staining with antibodies specific for mCXCR3 (Figure 6).  
Unexpectedly, cells transfected with pcDNA3.1_mCXCR3.m2 did not stain for mCXCR3 at high 
levels in multiple experiments (not shown).   
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The flow cytometric analyses indicated that subpopulations of cells transiently 
transfected with pcDNA3.1_mCXCR3.1 and pcDNA3.1_mCXCR3.m1 expressed higher levels of 
mCXCR3 as compared to cells transfected with the other two plasmids and negative controls.  
Altogether these data confirm that the transfections were successful, that a significant 
proportion of transfected cells are expressing the mCXCR3 protein, and that the commercially 
available mCXCR3 antibody binds to this protein. 
To examine the functionality of the receptor, chemotaxis assays were performed with 
cells transfected with pcDNA3.1_mCXCR3.1, pcDNA3.1_mCXCR3.2, pcDNA3.1_mCXCR3.m1, or 
plasmid vector only.  After 24 hours after of incubation, cells were washed and resuspended in 
0.1% BSA in RPMI medium.  Different concentrations of murine CXCL9 were placed on the 
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bottom of the chemotaxis plate, and the membrane was placed over the plate.  Cells were 
placed on top of the membrane and and the entire unit was incubated at 37oC.  Cells that 
migrated through the membrane were counted using a hemacytometer.  Only cells transfected 
with pcDNA3.1_mCXCR3.1 were tested with 1,000nM chemokine to conserve on reagents.   
Cells were found to successfully migrate to each chemokine (Figure 8).  The optimal 
concentration of mCXCL9 was 100 nM, whereas mCXCL10 stimulated chemotaxis optimally at 
10 nM.  mCXCL11 was more bioactive per unit mass and was most effective at 1 nM. 
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4E. Generation of L1.2 cell lines stably expressing mCXCR3.  To establish cell clones stably 
expressing mCXCR3, parental L1.2 cells were transfected via electroporation as described 
above.  These cells were not treated with sodium butyrate and were cultured in 10 mL of 
complete RPMI-1640 medium.  After four to five days of incubation in 37°C at 5% CO₂, cells 
were pelleted and resuspended in RPMI medium containing geneticin (1 mg/mL).  Cells that 
incorporated the mCXCR3-containing plasmid will have also gained the neomycin resistance 
gene (neor), which confers resistance to geneticin.  Cells were then diluted, seeded into each 
well of a 96-well plate, and left to incubate for one week.  The resulting foci of cells were 
collected and expanded in 24-well plates.  These primary clones were screened for 
functionality and expression of mCXCR3 by chemotaxis and flow cytometry, respectively.  
Primary clones resulting from cells transfected with pcDNA3.1_mCXCR3.1 were designated 
clones “1A”, “1B”, etc..  Cells grown from cells that were transfected with pcDNA3.1_mCXCR3.2 
were similarly named “2A”, “2B”, etc., and cells transfected with pcDNA3.1_mCXCR3.m1 were 
named “3A”, “3B”, etc.  The clones showing the highest levels of migration were used in a 
second round of single cell cloning.  They were diluted to 1 cell per every 3 wells of a flat-
bottom 96-well plate and cultured in the presence of geneticin for two weeks.  The resulting 
secondary clones were screened for migratory ability (Figure 8) and mCXCR3 levels (Figure 9), 
and the highest migrating clones were chosen as the stable cell clones to be used in the 
chemotaxis inhibition studies.  Secondary clones’ names incorporated the primary clone 
designation and a number, such as “1A.1” or “3E.4”.   
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Three cell clones were chosen for chemotaxis studies: 1E.s8, 2B.s5, and 3E.s4.  The 
1E.s8 and 2B.s5 cell clones both expressed wild type mCXCR3, and these two cell lines were 
chosen because they originated from different primary clones.  The 3E.s4 cell line expressed 
mutant mCXCR3.  All three expressed higher levels of mCXCR3 than other cell clones and 
responded chemotactically to mCXCL11. 
 
4F. Cytotoxicity assays.  To determine whether the compounds studied for potential 
chemotaxis inhibition were cytotoxic, the compounds were cultured with L1.2_mCXCR3.1E.s8 
cells and the effects on cell viability were measured. The standard conditions for a chemotaxis 
assay were replicated to examine if the highest concentrations of each test compound would 
exert cytotoxic effects during a chemotaxis experiment.  Cells were split each day for three days 
to keep them healthy, and then on the fourth day, a population of cells received an overnight 
sodium butyrate treatment.  Another population was not treated with sodium butyrate to test if 
overnight sodium butyrate treatment affects cell viability during a chemotaxis assay.  Cells 
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were incubated with these concentrations of compounds for three hours at 37°C in 5% CO2, 
and then were counted using trypan blue exclusion.   
Both the sodium  butyrate-treated (Figure 10A) and untreated cells (Figure 10B) 
showed similar results, as neither population of cells showed evidence of cytotoxic effects from 
the highest test concentrations of EGCG, gallotannin, murine X3P3, baicalin, and ginkgolide A.  
The baicalin and ginkgolide A samples contained 1.28% and 0.25% DMSO, respectively, and the 
vehicle controls, 0.25% DMSO and 1.28% DMSO, were also not cytotoxic.  However, cell 
viability significantly declined in the presence of 10% DMSO, or 20% DMSO, which served as 
positive controls for cytotoxicity, yielding approximately 80% dead cells after the incubation. 
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From these data, it was concluded that none of the compounds examined exerted cytotoxic 
effects at the highest test concentration, and any chemotactic inhibition that each compound 
might exhibit was unlikely to be the result of direct cell killing.  The data also indicate that 
overnight incubation with sodium butyrate did not render cells more prone to cell death during 
the chemotaxis assay on the day after incubation. 
 
4G. Chemotaxis inhibition assays.  .  To investigate the test compounds’ abilities to inhibit 
chemotaxis, each compound was examined in a chemotaxis inhibition assay.  Each assay was 
completed three separate times, with each sample performed in triplicate.  In the first set of 
chemotaxis experiments, the highest concentration of each compound was tested, based on the 
concentrations found via literature review.  Next, to examine dose-dependent effects, another 
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group of chemotaxis assays included a dilution series of each compound and an optimal 
concentration of chemokine.  These optimal concentrations were determined in earlier studies, 
as described above.  In the third series of assays, the highest concentration of each test 
compound was used with a titration of each chemokine to observe the effects of the compound 
on each concentration of chemokine.  .    
 During the first round of chemotaxis inhibition assays, the highest test concentration of 
each compound was used to inhibit chemotaxis towards mCXCL11, using the cell line 
L1.2_mCXCR3.1E.s8 (Figure 11).   EGCG and gallotannin both appeared to be potent inhibitors 
of chemotaxis.  These high concentrations of EGCG and gallotannin were able to prevent 
approximately 99% of migration.  Because baicalin and ginkgolide A samples contained 1.28% 
DMSO, their migration values were compared to the chemokine plus DMSO control.  Baicalin 
was slightly less effective than EGCG and gallotannin, as it inhibited about 80% of migration at 
200 μM, as compared to the migration towards mCXCL11 plus 1.28% DMSO.  Ginkgolide A 
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appeared to be even less effective, inhibiting chemotaxis by about 50% at the highest test 
concentration.  The difference between the numbers of cells that migrated to mCXCL11 only 
and mCXCL11 plus 100 μM X3P3 was not statistically significant, and because murine X3P3 
failed to show inhibitory properties at 100 μM, I did not include it in following studies. 
Titrations of each compound next were used to evaluate their ability to inhibit 
chemotaxis to each of the three mCXCR3 ligands in a dose-dependent manner.  Then a constant 
concentration of compound and a titration of chemokine was used.  All of these experiments 
were performed using the L1.2_mCXCR3.1E.s8 cell line.  These studies showed that EGCG and 
gallotannin strongly inhibited chemotaxis in a dose-dependent manner and were more potent 
than baicalin and ginkgolide A.  Baicalin showed moderate inhibitory effects at high 
concentrations, and ginkgolide A appeared to have slight inhibitory effects at its highest 
concentration.   
EGCG has recently been determined to be an effective inhibitor of human CXCR3 ligands 
by our laboratory (Dr. Shulin Qin, unpublished data).  Here, I have found that it is also a potent 
inhibitor of murine CXCR3 ligands, as shown in Figure 12.  At 100 μM, it prevented 
approximately 98-99% of migration towards the optimal concentration of each of the three 
chemokines.  For example, the average number of cells that migrated towards 1nM mCXCL11 
was approximately 50,000 cells, but only approximately 300 cells were observed to migrate 
towards 1nM mCXCL11 in the presence of 100 μM EGCG.  At a 10-fold lower concentration, 
EGCG was still able to prevent approximately 50% of migration towards the optimal 
concentration of each chemokine.  EGCG was also effective at preventing  chemotaxis towards 
different concentrations of chemokine.  When three different concentrations of each chemokine 
were tested, EGCG was able to inhibit almost all migration towards each chemokine, regardless 
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of concentration.  To determine whether EGCG might bind directly to chemokines, a binding 
assay performed by Dr. Jodi Craigo (University of Pittsburgh, Center for Vaccine Research) and 
revealed that EGCG binds directly to murine CXCR3 ligands (Figure 13), with apparently higher 
affinity for mCXCL11 than mCXCL9 and mCXCL10.  This direct binding by EGCG offers one 
potential mechanism by which it inhibits CXCR3 ligand driven chemotaxis. 
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Gallotannin appeared to be an even stronger inhibitor of chemotaxis.  It was most 
potent at 50 and 100 μM, at which it prevented approximately 99% of cell migration towards 
optimal concentrations of each chemokine.  At 10 μM, it reduced the number of cells migrating 
towards 10 nM mCXCL10 and 1 nM mCXCL11 by 80-85%.  The average number of cells 
migrating towards 1 nM mCXCL11 was about 55,000, and the average number of observed cells 
migrating towards 1 nM mCXCL11 plus 50 or 100 μM gallotannin was 300 and 100, 
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 respectively.  Similar to EGCG, 100 μM gallotannin inhibited almost all chemotaxis towards 
three different concentrations of each mCXCR3 ligand.   
The botanical baicalin showed moderate inhibitory effects on cell migration in a dose-
dependent manner.  It appeared to affect CXCL11 in a differently dose-dependent manner than 
with mCXCL9 and mCXCL10.  Murine CXCL11 appeared to be more sensitive to baicalin than 
mCXCL9 and mCXCL10.  At 200 μM, baicalin prevented about 85% of cell migration towards 1 
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nM mCXCL11, and 40-50% of migration towards optimal concentrations of mCXCL9 and 
mCXCL10.  Baicalin showed similar effects on the three different concentrations of chemokine, 
as it inhibited mCXCL11 more than the other two chemokines.  These data suggest that if 
baicalin exerts inhibitory effects by binding chemokines, it may have a higher affinity for 
mCXCL11.   
 The fourth botanical, ginkgolide A, was shown to be the weakest inhibitor of the four 
test compounds.  At the highest concentration of 80 μM, ginkgolide A inhibited approximately 
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60% of chemotaxis towards each of the three mCXCR3 ligands.  At 40 μM, it prevented only 20-
30% of cell migration towards each chemokine, and it showed no significant effects at reduced 
concentrations.  Its effects were consistent between each chemokine and for each 
concentration of chemokine.   
 
4H. Chemotaxis inhibition with other cell lines.  To ensure that the test compounds’ effects 
were not unique to the L1.2_mCXCR3.1E.s8 cell clone, two other cell clones were used in 
chemotaxis inhibition studies: L1.2_mCXCR3.2B.s5 and L1.2_mCXCR3.3E.s4.  
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L1.2_mCXCR3.2B.s5 expressed wild-type mCXCR3, whereas L1.2_mCXCR3.3E.s4 expressed the 
mutant form of mCXCR3 described previously.  The highest test concentration of each botanical 
compound was used to test the compound’s ability to inhibit cell migration towards mCXCL9, 
mCXCL10, and mCXCL11.  Each test compound affected both cell clones similarly to the 
L1.2_mCXCR3.1E.s8 cell line (Figures 17 and 18). EGCG and gallotannin strongly inhibited 
chemotaxis towards the three chemokines, and baicalin and ginkgolide A had moderate effects. 
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 For both cell clones, EGCG and gallotannin inhibited approximately 98-99% of cell 
migration to each chemokine, as they did in previous chemotaxis experiments using 
L1.2_mCXCR3.1E.s8.  Murine CXCL11 also appeared to be more sensitive to baicalin compared 
to mCXCL10 and mCXCL11, as 200 μM baicalin prevented 70-80% of migration towards 
mCXCL11 for each cell line.  It inhibited approximately 40-50% of migration towards mCXCL9 
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and mCXCL10 for both of the cell clones.  The effects of ginkgolide A were consistent between 
each of the cell clones tested, as it inhibited at most 50% of migration towards each chemokine. 
The cell clone expressing mutant mCXCR3 migrated at higher levels to each chemokine, as 
compared to the L1.2_mCXCR3.1E.s8 and L1.2_mCXCR3.2B.s5 cell lines.  For example, the 
average number of L1.2_mCXCR3.3E.s4 cells migrating towards 1 nM mCXCL11 was 70,000, 
whereas the corresponding number of L1.2_mCXCR3.2B.s5 cells was 53,000.  An average of 
51,000 cells from the mutant mCXCR3-expressing cell line migrated towards 100 nM mCXCL9, 
compared to an average of 27,000 cells from the L1.2_mCXCR3.2B.s5 cell line.  These results 
suggest that the mutant mCXCR3 protein does not have diminished capacity to bind or respond 
to mCXCL9.  However, only one mutant mCXCR3-expressing cell clone was examined, and other 
such cell clones must be examined 
 
4I. Chemotaxis inhibition with EGCG analogs.  To investigate which functional groups of 
EGCG might be important for inhibition of chemotaxis, three compounds with similar 
structures were used in chemotaxis inhibition assays.  These analogs of EGCG are 
epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC), and their structures are 
depicted in Figure 1.   
 The most effective compound of these three green tea polyphenols was ECG, which, at 
100 μM, was able to inhibit approximately 50% of migration toward mCXCL9 and mCXCL10 
and about 75-80% of chemotaxis toward mCXCL11 in a dose-dependent manner (Figure 19).  
In Figure 19, the light blue bars on the right represent mCXCL9, the set of royal blue bars in the 
middle correspond to mCXCL10, and the navy blue bars on the right denote mCXCL11.   Murine 
CXCL11 appeared to be the most sensitive to the inhibitory effect of each compound.  The 
highest concentration of EGC and EC prevented approximately 50% of migration toward 
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mCXCL9 and mCXCL10, and about 60% of chemotaxis toward mCXCL11. 
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4J. Summary.  In summary, each botanical compound examined had different inhibitory effects 
on the cell migration of three cell lines expressing mCXCR3.  Gallotannin seemed to be the most 
potent inhibitor, followed closely by EGCG.  Baicalin was able to inhibit 50% of migration 
towards mCXCL9 and mCXCL10 at the highest test concentration, but it inhibited migration to 
mCXCL11 more strongly.  The fourth compound, ginkgolide A, was somewhat effective at the 
highest test concentration, with at most 40% inhibition of chemotaxis.  These results were 
consistent for the three cell lines tested.  Among the EGCG analog compounds tested, ECG was 
the strongest inhibitor of chemotaxis, although it was not as potent as EGCG.  It was able to 
inhibit migration induced by mCXCL11 by about 80%.  EGC and EC were both weaker 
inhibitors than ECG, as 100 μM of each compound prevented 50% of migration toward 
mCXCL11. 
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CHAPTER 5: DISCUSSION 
 
5A. Overview. CXCR3 is thought to be involved in numerous inflammatory disorders.  In an 
effort to research new therapies for such diseases, I investigated several compounds that may 
modulate CXCR3-ligand interactions using an in vitro mouse model.  I used this model in 
preparation for establishing an in vivo model that would seek to accurately reflect the effects of 
the inhibitory compounds in humans.  The main purpose of this study was to study the 
inhibitory properties of botanical compounds and a murine CXCR3 peptidergic mimetic on 
murine CXCR3 ligand function.   
 
5B. Murine X3P3.  In this project, I sought to determine if a peptide mimetic of the ECL-2 of 
murine CXCR3 would inhibit the activity of mCXCR3 ligands.   A small number of previous 
studies have examined peptide mimetics of chemokine receptor extracellular domains.  CCR5 
mimetics are known to bind the HIV glycoprotein gp120, a CCR5 ligand, as demonstrated by 
Agrawal et al.79.  The second extracellular loop (ECL-2) of CCR5 was shown to bind the gp120 of 
an R5 HIV strain and inhibit viral fusion and infection in a dose-dependent manner.  However, 
the effects of this mimetic on the natural ligands for CCR5 was not examined.  Human X3P3, an 
ECL-2 mimetic of CXCR3, has also been determined by our group to bind CXCR3 ligands and 
exert dose-dependent inhibition of chemotaxis (S. Qin, unpublished data).  Thus, it has been 
established some ECL-2 peptide mimetics are able to bind several chemokine receptor ligands.  
However, whereas human X3P3 is efficient at inhibiting chemotaxis towards CXCR3 ligands, its 
murine counterpart mX3P3 did not significantly inhibit migration of murine CXCR3+ cells.  This 
incongruity may be attributed to the possibility that that murine X3P3, when presented 
separately from the chemokine receptor as a whole, has a different structure.  Whereas human 
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X3P3 retains a conformation that is able to bind ligands, murine X3P3 likely assumes a 
structure that is unable to bind CXCR3 ligands.  Murine X3P3 may not bind murine CXCR3 
ligands with as much affinity as human X3P3 binds human CXCR3 ligands, and perhaps murine 
CXCR3 ligands bind other ECLs with higher affinity due to a difference in chemokine receptor 
structure.  In any case, the in vitro data suggest that the current form of murine X3P3 likely will 
not effectively inhibit mCXCR3 ligands in vivo.  More research is needed to discover if an ECL-2 
peptide mimetic or other ECL-based mimetics will inhibit CXCR3-ligand interactions. 
 
5C. Botanical compounds. Some of the botanical test compounds, however, successfully 
inhibited mCXCR3 ligand function, and the data suggest that EGCG and gallotannin will be 
strong inhibitors of mCXCR3 ligands in mice.  EGCG has been tested in chemotaxis inhibition 
assays using human cells (S. Qin), and the pattern of inhibition in murine and human cells is 
similar (Figure 20).  Thus, it may be anticipated that EGCG will have anti-inflammatory effects 
in mice similarly to humans in vivo.  Gallotannin, baicalin, and ginkolide A have not yet been 
examined in our hands with human cells, and these studies may be pursued in the future to 
determine if these botanicals inhibit the migration of human cells to the same extent as they 
inhibited murine cells.  If so, the murine model may be suitable for in vivo studies of infection 
and inflammation.  
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 To understand why some compounds inhibited chemotaxis and others did not, it will 
be helpful to compare their structures.  When comparing the structures of successful versus 
ineffective compounds, a pattern emerges.  The more hydroxyl groups a compound has, the 
more potent it is at inhibiting chemotaxis.  Gallotannin has by far the most hydroxyl groups and 
was the strongest inhibitor, followed by EGCG, then baicalin, then ginkoglide A.  Ginkgolide A is 
the weakest inhibitor, and as the pattern predicts, has the least hydroxyl groups.  The mCXCR3 
 45 
ligands may prefer to bind these groups due to structural complementarity or perhaps due to 
their negative charge.  These data are consistent with past studies’ findings that chemokines 
generally must be able to bind to glycosaminoglycans (GAGs) to function in vivo80.  GAGs are 
linear polysaccharides found on cell surfaces and within the extracellular matrix, and they are 
acidic, very negatively-charged, and highly-sulfated with the exception of hyaluronan.  GAGs 
are long chains made up of disaccharide units, also called disaccharide repeating regions81.  A 
representative disaccharide unit of each type of GAG is shown in Figure 21.  It is generally 
believed that GAGs selectively bind most chemokines and help establish chemokine gradients82. 
Notably, GAGs and the botanicals that most potently inhibited chemotaxis – gallotannin 
and EGCG – share similar properties.  In solution, the hydroxyl groups on gallotannin and EGCG 
would donate their hydrogens.  Gallotannin and EGCG would become negatively charged and 
acidic, as are GAGs, which are known to bind chemokines.  There is also a dose-dependency of 
sorts, as gallotannin has more hydroxyl groups and more of a negative charge, it is able to 
inhibit migration more efficiently.  Thus, it is a plausible theory that EGCG and gallotannin are 
able to bind mCXCR3 ligands on GAG-binding domains due to their hydroxyl groups and 
negative charge.  They form complexes with the chemokines and subsequently prevent them 
from binding with their receptors.  This is similar to the activity of soluble GAGs, as described 
by a study by Kuschert et al83.  Soluble GAGs were shown to bind to IL-8 and MIP-1α and inhibit 
binding to their respective receptors.  Furthermore, soluble heparin was able to inhibit IL-8 
induced intracellular calcium mobilization in neutrophils in a dose-dependent manner.   
To investigate the hypothesis that EGCG and gallotannin inhibit chemokine function 
similarly to soluble GAGs, it must be determined if they bind mCXCR3 ligands.  EGCG has been 
shown to bind directly to human and murine CXCR3 ligands (J. Craigo, Figure 13), but such 
studies have not yet been performed with gallotannin.  These studies may be performed in the 
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future to verify the binding of gallotannin to mCXCR3 ligands.  There is a caveat in assuming 
gallotannin is inhibiting the function of mCXCR3 ligands simply by binding them in solution.  
During cytotoxicity studies, a slightly grainy residue was observed when examining cells under 
the microscope, suggesting that gallotannin was precipitating out of solution when dissolved in 
chemotaxis medium.  Although this residue was not observed when examining samples after a 
chemotaxis assay, the compound may be coming out of solution and drawing the chemokines 
out of solution as well, instead of simply binding them free in solution.  Further studies are 
required to determine the mechanism by which gallotannin inhibits chemokine function. 
 If EGCG and gallotannin bind the GAG-binding domains on mCXCR3 ligands, it is 
possible that these compounds may prevent chemokine binding to GAGs and subsequently 
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impede the establishment of haplotactic chemokine gradients in the extracellular matrix.  
While it is not necessary for chemokines to form a gradient to induce chemotaxis84, the 
disruption of a chemokine gradient would interfere with or reduce cell migration induced by 
that particular chemokine.  Without the establishment of a gradient, chemokines can also 
stimulate chemotaxis by a process called chemokinesis, if they are matrix-bound and are 
presented close together in concentric rings85.  The interference of GAG-chemokine binding by 
EGCG and gallotannin will also interfere with chemokinesis, as they will prevent chemokines 
from becoming matrix-bound. 
 
5D. EGCG analogs.  The data here suggest that amongst the botanicals examined, the more 
hydroxyl groups or negative charge a compound has, the more potently it inhibits chemotaxis.  
This pattern is also seen when comparing the inhibitory ability of EGCG and its analogs, which 
are also green tea polyphenols.  EGCG is the strongest inhibitor, followed by ECG, then EGC and 
EC.  EGCG has eight hydroxyl groups, ECG has seven, EGC has six, and EC has five.  However, this 
observation is not enough to fully explain why EGCG is a much stronger inhibitor of mCXCR3 
ligands than is ECG, with a difference of only one hydroxyl group.  The difference in potency is 
likely due to differences in structure, although EGCG and ECG are identical in structure except 
for the one hydroxyl group.  Thus, EGCG may be better able to bind chemokines because of a 
certain conformational advantage.   
 
5E. Mutant mCXCR3. 
I hypothesized that the mutant form of mCXCR3 may be unable or less able to efficiently 
bind mCXCL9 due to two amino acid substitutions located in its N-terminus.  The 16 amino 
acids located in the N-terminus of human CXCR3 are thought to be important for binding 
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CXCL986.  However, the L1.2_mCXCR3.3E.s8 cell line was not impaired in its ability to respond 
to mCXCL9.  This observation suggests that the glutamine and valine at positions 4 and 5 are 
not essential for binding mCXCL9 and responding to it, or that the two amino acid substitutions 
did not substantially change the folding of the N-terminus of mCXCR3.  This may be possible, as 
that substituted amino acids have the same charge as the original amino acids.  However, only 
one mutant mCXCR3-expressing cell clone was analyzed in this study and analysis of additional 
clones will help to confirm this finding.  
 
5F. Future studies.  Several studies that may helpful for understanding the data generated in 
the current study have already been mentioned.  Other cell clones expressing the mutant form 
of mCXCR3 could be analyzed to see if the results observed in this study are consistent with 
these other cell lines, and to further understand the effect, if any, of the two point mutations in 
the extracellular C-terminal region.  Other mutation studies may include forms of mCXCR3 that 
respond specifically to each chemokine and determine if each mutant is affected differently by 
mCXCR3 inhibitors like EGCG.  These mutants would contain specific mutations in multiple 
regions that bind mCXCL9, mCXCL10, and mCXCL11.  A third type of mutant study can include 
GAG-binding domains, such as  the study by Ali et al.87.  In this study, a mutant form of CCL7 
that did not bind heparin was constructed.  This mutant was able to generate a chemotactic 
response in vitro, but failed to do so in vivo.  One of the hypotheses discussed earlier is that 
EGCG and gallotannin are effective at binding mCXCL9 ligands due to their negative charges, 
which GAGs also have.  GAG-binding mutants may be analyzed to determine if they are 
refractory to the inhibitory properties of EGCG and gallotannin.  If so, this will confirm that 
negative charges are important properties for mCXCR3 inhibitors. 
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 An additional study may be performed to follow up on the negative data concerning 
murine X3P3.  Since it did not appear to inhibit mCXCR3 ligand function efficiently, future 
studies may focus on finding a peptide mimetic of mCXCR3 that is more effective at inhibiting 
mCXCR3-ligand interactions.  Perhaps it would be useful to study how murine X3P3 can be 
modified to become a more effective inhibitor.  A hypothesis about mX3P3 discussed 
previously is that it may not fold correctly when separated from the mCXCR3 protein, thus 
future studies may address how mX3P3 can be induced to fold in different ways that are more 
conducive to binding mCXCR3 ligands.  
 Lastly, an approach that may be useful in illuminating the method by which EGCG and 
gallotannin inhibit mCXCR3 ligand function is a binding study.  This has been accomplished in 
the past using Biacore technology (Figure 13), which measures the binding of a molecule bound 
on a chip to another molecule passed over the chip in a flow channel.  Another binding study 
uses radioactive 125I to label chemokines, and these chemokines are incubated with the 
compound in question88.  Cells are then centrifuged, and cell-associated radioactivity is counted 
with a gamma counter. 
 
5G. Public health relevance. EGCG and gallotannin are able to modulate CXCR3-ligand 
interactions, and they may be novel candidates for development into therapeutics for CXCR3-
mediated inflammatory diseases, and possibly other chemokine-related inflammatory diseases.  
Currently there is a demand for naturally-derived therapies with fewer side effects, and 
botanicals are excellent sources for such therapies.   
 While EGCG and gallotannin may be able to regulate inflammation, they may also non-
specifically bind other chemokines due to their negative charges or through their GAG-binding 
domains.  Most chemokines in addition to CXCL9, CXCL10, and CXCL11 are positively charged, 
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including chemokines involved homeostatic and inflammatory processes.  Thus, EGCG and 
gallotannin may interfere with important physiological processes such as organogenesis and 
normal inflammatory responses to combat pathogens.  However, it must be recognized that 
green and black teas have been consumed for millennia with no clear detriment to health or 
fetal development.  To prevent this interference, dosages of EGCG and gallotannin must be 
further researched, and low dosages that will allow these processes to occur should be used.  
EGCG and gallotannin, may also interfere with vaccination.  Inflammatory responses are 
necessary for an effective vaccination, and inhibition of inflammatory chemokines would be 
counterproductive to the purposes of vaccination.  It may be a useful recommendation for a 
patient to refrain from taking EGCG, gallotannin, or foods and supplements that contain these 
compounds while being vaccinated. 
 
5H. Model of inhibition.  It has been discovered that EGCG and gallotannin can inhibit 
chemotaxis driven by mCXCR3 ligands, and it has been shown that EGCG can bind mCXCR3 
ligands.  The model of inhibition proposed in this study, then, is that compounds like EGCG and 
gallotannin inhibit mCXCL9 ligand function by binding the chemokines and preventing them 
from interacting with their receptor (Figure 22).  This inhibitory action may be beneficial in 
treatments for inflammatory disorders such as rheumatoid arthritis and Crohn’s disease.  In 
rheumatoid arthritis, the lining of the joints – called the synovium – become inflamed due to 
the recruitment of Th-1 type T lymphocytes.  Because CXCR3 is preferentially expressed on 
these cells, a CXCR3 inhibitor such as EGCG may prevent the migration of Th-1 cells to the 
synovium by binding CXCR3 ligands, thereby reducing the severity of inflammation and 
alleviating the symptoms of rheumatoid arthritis.  
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 The data generated in this study suggest that inhibitors like EGCG and gallotannin may 
bind the GAG-binding domains of CXCR3 ligands, not only preventing their interaction with 
CXCR3 but also with GAGs in the extracellular matrix.  This could lead to interference with the 
formation of haptotactic chemokine gradients, as the matrix would not be able to efficiently 
immobilize CXCR3 ligands.   
 Human X3P3 studies performed in our laboratory indicate that X3P3 may also be a 
strong CXCR3 inhibitor.  It has been demonstrated to bind CXCR3 ligands and thereby prevent 
CXCR3-ligand binding.    Murine X3P3 has not been shown to have this ability.  More studies are 
necessary to determine why it is ineffective at inhibiting chemotaxis, how mX3P3 may be 
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modified to become a strong inhibitor, and if other ECL-based peptide mimetics of murine 
CXCR3 will be effective. 
 
 
5I.  Conclusion.  In this study, EGCG and gallotannin have been revealed to be strong inhibitors 
of mCXCR3 ligand function.  Because of their inhibitory properties, they are strong candidates 
for the development of therapies for CXCR3-mediated inflammatory disorders.  The results 
observed in this study suggest that the mouse model may be used in future in vivo studies to 
examine EGCG and gallotannin as CXCR3 inhibitors, and such studies are in progress.  Other 
futures studies may include binding assays and the use of GAG-binding domain mutants, which 
may help determine how EGCG, gallotannin, and other compounds inhibit murine and human 
CXCR3 ligand function, and how other compounds such as mX3P3 can be modified to more 
efficiently inhibit mCXCR3- and CXCR3-ligand interactions. 
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